Shares of DexCom, Inc. (NASDAQ:DXCM) were down 0.3% during trading on Friday . The stock traded as low as $71.09 and last traded at $71.00. Approximately 633,336 shares traded hands during trading, a decline of 46% from the average daily volume of 1,162,200 shares. The stock had previously closed at $71.23.

Several analysts have recently commented on DXCM shares. Piper Jaffray Companies restated an “overweight” rating and set a $78.00 price objective on shares of DexCom in a research report on Monday, May 22nd. Canaccord Genuity restated a “buy” rating and set a $90.00 price objective on shares of DexCom in a research report on Wednesday, June 7th. BidaskClub upgraded shares of DexCom from a “sell” rating to a “hold” rating in a research report on Thursday, June 15th. BMO Capital Markets restated a “buy” rating and set a $105.00 price objective on shares of DexCom in a research report on Thursday, July 13th. Finally, Cowen and Company restated a “buy” rating and set a $90.00 price objective on shares of DexCom in a research report on Friday, July 14th. Six analysts have rated the stock with a hold rating and fifteen have given a buy rating to the stock. DexCom has a consensus rating of “Buy” and an average price target of $87.00.

The company’s market cap is $6.17 billion. The stock’s 50 day moving average price is $71.87 and its 200 day moving average price is $74.35.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Tuesday, August 1st. The medical device company reported ($0.16) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.23) by $0.07. The company had revenue of $170.60 million during the quarter, compared to analysts’ expectations of $166.54 million. DexCom had a negative net margin of 10.27% and a negative return on equity of 27.90%. The firm’s revenue for the quarter was up 24.3% on a year-over-year basis. During the same period in the prior year, the business posted ($0.24) earnings per share. Analysts predict that DexCom, Inc. will post ($0.77) earnings per share for the current year.

In other news, EVP Steven Robert Pacelli sold 1,450 shares of the stock in a transaction dated Friday, June 23rd. The shares were sold at an average price of $78.19, for a total value of $113,375.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Andrew K. Balo sold 3,200 shares of the stock in a transaction dated Monday, June 12th. The shares were sold at an average price of $69.06, for a total transaction of $220,992.00. The disclosure for this sale can be found here. Insiders have sold 32,179 shares of company stock valued at $2,282,217 over the last 90 days. 1.70% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently modified their holdings of the company. Independent Portfolio Consultants Inc. raised its position in shares of DexCom by 0.4% in the second quarter. Independent Portfolio Consultants Inc. now owns 2,499 shares of the medical device company’s stock valued at $183,000 after buying an additional 9 shares during the last quarter. Bbva Compass Bancshares Inc. raised its position in shares of DexCom by 1.9% in the second quarter. Bbva Compass Bancshares Inc. now owns 3,670 shares of the medical device company’s stock valued at $268,000 after buying an additional 69 shares during the last quarter. Public Employees Retirement Association of Colorado raised its position in shares of DexCom by 0.4% in the second quarter. Public Employees Retirement Association of Colorado now owns 18,613 shares of the medical device company’s stock valued at $1,362,000 after buying an additional 83 shares during the last quarter. King Luther Capital Management Corp raised its position in shares of DexCom by 0.7% in the first quarter. King Luther Capital Management Corp now owns 12,105 shares of the medical device company’s stock valued at $1,026,000 after buying an additional 90 shares during the last quarter. Finally, Raymond James Financial Services Advisors Inc. raised its position in shares of DexCom by 0.8% in the first quarter. Raymond James Financial Services Advisors Inc. now owns 18,077 shares of the medical device company’s stock valued at $1,532,000 after buying an additional 140 shares during the last quarter.

COPYRIGHT VIOLATION WARNING: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The original version of this news story can be accessed at https://www.dailypolitical.com/2017/09/08/dexcom-inc-dxcm-shares-down-0-3-2.html.

DexCom Company Profile

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.